RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer

Trial Profile

RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs RC 48 (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors RemeGen
  • Most Recent Events

    • 16 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top